Manufacturing Misery in Vaccines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturing Misery in Vaccines
Vaccine manufacturing was predicted in 2008 to be on the cusp of a golden era, but instead the industry has experienced cost pressures, high-profile liability cases and production setbacks.


Pharmaceutical Technology Europe


References

1. L. Galambos, What are the Prospects for a New Golden Era in Vaccines? (UK Vaccines Group, UK, 2008).

2. Pharmaletter website, "Novartis' flu vaccines suspended in several countries on suspected quality issues", http://www.thepharmaletter.com/, accessed 12 Dec., 2012.

3. Fiercepharma website, "Italy bans Novartis vaccines even after company assures their safety", http://www.fiercepharma.com/, accessed 12 Dec., 2012.

4. Reuters website, "France halts sale of Novartis flu vaccine", http://uk.reuters.com/, accessed 12 Dec., 2012.

5. Deutsche Welle website, "Germany moves to cut off vaccine shortage", http://www.dw.de/, accessed 12 Dec., 2012.

6. The Globe and Mail website, "Canada suspends distribution of Novartis flu shots", http://www.theglobeandmail.com/, accessed 12 Dec., 2012.

7. Fiercepharma website, "Novartis plant delay, vaccine woes steal spotlight", http://www.fiercepharma.com/, accessed 12 Dec., 2012.

8. Health Canada website, "Health Canada Endorsed Important Safety Information on Infanrix Hexa", http://www.hc-sc.gc.ca/, accessed 12 Dec., 2012.

9. In-pharmatechnologist website, "GSK pulls vaccine batch in Canada over contamination concerns", http://www.in-pharmatechnologist.com/, accessed 12 Dec., 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here